Fexofenadine/pseudoephedrine
In today's world, Fexofenadine/pseudoephedrine has been a topic that has generated a lot of interest and debate. Whether due to its historical relevance, its impact on current society or its influence in different areas, Fexofenadine/pseudoephedrine has captured the attention of many. From its emergence to the present, Fexofenadine/pseudoephedrine has raised a wide range of opinions and has been the subject of numerous studies and research. In this article, we will explore in depth the different aspects related to Fexofenadine/pseudoephedrine, analyzing its importance, its implications and its evolution over time.
| Combination of | |
|---|---|
| Fexofenadine | Antihistamine |
| Pseudoephedrine | Nasal decongestant |
| Clinical data | |
| Trade names | Allegra-D |
| MedlinePlus | a601053 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Fexofenadine/pseudoephedrine, sold under the brand name Allegra-D among others, is a fixed-dose combination medication used for the treatment of nasal congestion and other symptoms of allergies[4] and the common cold.[2] It contains fexofenadine, as the hydrochloride, an antihistamine; and pseudoephedrine, as the hydrochloride, a nasal decongestant.[2]
In 2021, it was the 279th most commonly prescribed medication in the United States, with more than 800,000 prescriptions.[5][6]
References
- ^ "Allegra-D Product information". Health Canada. 25 April 2012. Retrieved 2 June 2022.
- ^ a b c "Allegra-D Allergy and Congestion- fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, film coated, extended release". DailyMed. 3 December 2020. Retrieved 2 June 2022.
- ^ "Allegra-D Allergy and Congestion- fexofenadine hydrochloride and pseudoephedrine hydrochloride tablet, film coated, extended release". DailyMed. 30 August 2021. Retrieved 2 June 2022.
- ^ Mansfield LE (May 2006). "Once-daily immediate-release fexofenadine and sustained-release pseudoephedrine combination: a new treatment option for allergic rhinitis". Expert Opinion on Pharmacotherapy. 7 (7): 941–51. doi:10.1517/14656566.7.7.941. PMID 16634716. S2CID 23165002.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Fexofenadine; Pseudoephedrine - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |